Graves ophthalmopathy
Drug research and approvals for graves ophthalmopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 64 studies of graves ophthalmopathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 64
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye DiseaseNCT07885605 · Phase 1 · Ethyreal Bio, Inc. · starts Jul 6, 2026
- Comparative Evaluation of 68Ga-FAPI and 68Ga-DOTATATE PET/CT and PET/MRI in Thyroid Eye DiseaseNCT07835607 · Not reported · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · starts Nov 14, 2025
- An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to TeprotumumabNCT07832136 · Phase 4 · Viridian Therapeutics, Inc. · starts Oct 19, 2026
- Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' DiseaseNCT07812194 · Not reported · University of Copenhagen · starts Oct 16, 2026
- Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)NCT07753603 · Phase 3 · Sling Therapeutics, Inc. · starts Aug 4, 2026
- A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease…NCT07722546 · Phase 2 · Biogen · starts Jul 30, 2026
- Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE…NCT07716397 · Not reported · Shanghai Changzheng Hospital · starts Jan 1, 2026
- Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' DiseaseNCT07682896 · Phase 2 · Yarrow Bioscience, Inc. · starts Jun 10, 2026
- Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' DiseaseNCT07661056 · Phase 3 · Biohaven Therapeutics Ltd. · starts Jun 26, 2026
Approved 1
- TeprotumumabInsulin-like growth factor I receptor antagonist
Phase 3 10
- BatoclimabIgG receptor FcRn large subunit p51 inhibitor
- MethimazoleThyroid peroxidase inhibitor
- BimatoprostProstanoid FP receptor agonist
- PropylthiouracilThyroid peroxidase inhibitor
- AtorvastatinHMG-CoA reductase inhibitor
- SimvastatinHMG-CoA reductase inhibitor
- SecukinumabInterleukin 17A inhibitor
- SatralizumabIL6Ralpha/GP130 antagonist
- Efgartigimod alfaIgG receptor FcRn large subunit p51 antagonist
- Selenic acid
Phase 2 12
- RituximabB-lymphocyte antigen CD20 binding agent
- SirolimusFK506-binding protein 1A inhibitor
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- TocilizumabInterleukin-6 receptor alpha subunit inhibitor
- CelecoxibCyclooxygenase-2 inhibitor
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- AfliberceptVascular endothelial growth factor A inhibitor
- LanreotideSomatostatin receptor 5 agonist
- PrednisoneGlucocorticoid receptor agonist
- OtelixizumabT-cell surface glycoprotein CD3 epsilon chain binding agent
- VunakizumabInterleukin 17A inhibitor
- Selenium
Phase 1 or earlier 3
- AzithromycinBacterial 70S ribosome inhibitor
- Lonigutamab
- VeligrotugInsulin-like growth factor I receptor antagonist
How its trials ended
149 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 25 whose ending is known, 32% met their primary endpoint, 4% missed it and 64% stopped early.
- Ongoing5436%
- Completed, result not reported4329%
- Status unknown2718%
- Stopped: other or unclear96%
- Met its primary endpoint85%
- Stopped: sponsor or business decision32%
- Stopped: lack of efficacy21%
- Stopped: enrollment or feasibility21%
- Missed its primary endpoint11%
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jun 19, 2025 | TepezzaTeprotumumab | Amgen Europe B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA